PPAR
Os receptores ativados por proliferadores de peroxissomas (PPARs) são um grupo de proteínas receptoras nucleares que funcionam como fatores de transcrição, regulando a expressão de genes envolvidos no metabolismo, particularmente no armazenamento de ácidos graxos e no metabolismo da glicose. Inibidores de PPAR são ferramentas importantes para o estudo de distúrbios metabólicos como diabetes, obesidade e doenças cardiovasculares. Esses inibidores podem modular o metabolismo lipídico, a sensibilidade à insulina e a inflamação, tornando-os valiosos na pesquisa terapêutica. Na CymitQuimica, oferecemos uma gama de inibidores de PPAR para apoiar sua pesquisa em doenças metabólicas, endocrinologia e desenvolvimento de medicamentos.
Foram encontrados 172 produtos para "PPAR".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Halofenate
CAS:Halofenate is an inhibitor for hypertriglyceridemia, effectively lowering serum triglyceride levels while having minimal impact on serum cholesterol. Additionally, it reduces serum uric acid and promotes uric acid excretion independent of glomerular filtration rate. Halofenate is associated with a significant increase in plasma thyroxine (T4), along with reductions in protein-bound iodine and T4. It can displace T4 from thyroid-binding proteins, which may influence thyroid function in the body.Fórmula:C19H17ClF3NO4Cor e Forma:SolidPeso molecular:415.79PPARγ agonist 10
CAS:PPARγ agonist 10 (compound 33g) serves as a PPARγ agonist, enhancing insulin secretion, glucose uptake, and insulin sensitivity in βTC6 cells [1].Fórmula:C17H14N4O3S2Cor e Forma:SolidPeso molecular:386.45PPARγ agonist 17
CAS:PPARγ agonist17 (Compound C1) is an orally active PPARγ agonist. It enhances PPARγ activity, arrests the cell cycle of HT-29 cells at the G2/M phase, inhibits cell migration, and induces apoptosis. PPARγ agonist17 exhibits broad-spectrum antiproliferative activity against cancer cells with relatively low toxicity to normal cells and does not cross the blood-brain barrier.Fórmula:C48H63NO7Cor e Forma:SolidPeso molecular:766.016PPARγ phosphorylation inhibitor 1
CAS:PPARγ phosphorylation inhibitor 1, PPARγ agonist (IC50=24 nM), inhibits CDK5-mediated Ser273 phosphorylation, antidiabetic activity.Fórmula:C22H14Cl2N2O4Pureza:99.86%Cor e Forma:White SolidPeso molecular:441.26Fonadelpar
CAS:Fonadelpar is an agonist of PPARδ. It also is used in the research of neuroparalytic keratopathy.Fórmula:C25H23F3N2O4SPureza:98%Cor e Forma:SolidPeso molecular:504.52PPARγ-IN-5
CAS:PPARγ-IN-5 (Compound A3) is an inhibitor of PPARγ. In liver cells, it reduces lipid accumulation and shows no significant cytotoxicity in HepG2 cells at a concentration of 400 µM. PPARγ-IN-5 is applicable for research on non-alcoholic fatty liver disease.Fórmula:C22H23ClO7Cor e Forma:SolidPeso molecular:434.867SR 11023
CAS:SR 11023, an orally active PPAR γ antagonist, exhibits an IC 50 value of 109 nM and is significant in diabetes research [1].Fórmula:C33H36N2O3Cor e Forma:SolidPeso molecular:508.65PPARα/δ agonist 3
CAS:PPARα/δ agonist 3 (Compound 8) is an orally active PPAR agonist capable of activating PPARα, PPARδ, and PPARγ, with EC50 values of 5.6 nM, 3.4 nM, and 1278 nM, respectively. It exhibits anti-cholestatic activity in mouse models of cholestatic liver disease induced by ANIT or CDCA.Fórmula:C23H25F3N2O4Cor e Forma:SolidPeso molecular:450.451Anti-NASH agent 2
CAS:Anti-NASH agent 2 (compound 21) is an inhibitor of neolipogenesis activity and α-SMA gene expression. It improves hepatic steatosis, edema, inflammatory infiltration, and liver fibrosis in NASH mouse models.
Fórmula:C32H51N3O2Cor e Forma:SolidPeso molecular:509.766PPARδ agonist 11
CAS:Compound 11, a selective PPARδ agonist, demonstrates an EC50 of 20 nM, indicating its high affinity for PPARδ receptors. This compound efficiently reduces levels of nitric oxide (NO), as well as the pro-inflammatory cytokines TNFα and IL-6 in LPS-stimulated RAW264.7 cells via the NF-κB pathway, showcasing its anti-inflammatory properties. Additionally, Compound 11 exhibits remarkable stability in human liver microsomes and plasma. It significantly ameliorates foot edema induced by Carrageenan, displaying favorable pharmacokinetic properties with a bioavailability of approximately 100%.Fórmula:C19H15F3N2O3S2Cor e Forma:SolidPeso molecular:440.46Amezalpat
CAS:Amezalpat is a PPARα antagonist with an IC50 of 58 nM [nanomolar]. Amezalpat also exhibits antitumor activity.Fórmula:C34H41N3O4Cor e Forma:SolidPeso molecular:555.707Aleglitazar
CAS:Aleglitazar (R1439) (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively.Fórmula:C24H23NO5SPureza:99.03%Cor e Forma:White SolidPeso molecular:437.51
